Kornimate/medical-research-clean huggingface dataset:
semi-rigid ureteroscopy versus flexible ureteroscopy for the treatment of proximal ureteric stone

Conditions: Ureteric Stone; Stone Ureter

Summary: the present study is randomized in nature, comparing the stone free rate and complications rate between semi-rigid ureteroscopy (sr-urs) and flexible ureteroscopy (f-urs) for the treatment of proximal ureteric stone (pus), whereby the preoperative assessments, procedure and reporting of outcomes will all be standardized.

there are various treatment options that can be used for the treatment of pus, which include extracorporeal shockwave lithotripsy (swl), ureteroscopy (urs), percutaneous nephrolithotomy (pcnl), antegrade uretero-lithotripsy, laparoscopy, and rarely, open surgical procedures. however, the standard, and the most frequently used modalities are swl and ureteroscopy. when comparing the effectiveness in the treatment of proximal ureteric stone (pus) between swl and urs, swl has lower rates of complication and morbidity, but urs has a higher likelihood of successfully treating the patient within a single procedure. additionally, with the advancements in technology and miniaturization of the ureteroscopes, along with the presence of auxiliary instruments such as holmium laser and retrieval baskets, ureteroscopy is more widely used. in the proximal ureter, sr-urs tends to encounter difficulties in accessing the stone, but f-urs aids in overcoming those difficulties. as a result, the use of f-urs for pus has indicated a strong success rate with lower likelihood of complications. when comparing the drawbacks of the two types of modalities, f-urs tends to be more expensive, and requires auxiliary instruments. and sr-urs tends to have lower success rate along with an increased rate in complications. the precedence of furs over sr-urs in the treatment of pus is yet to be extensively studied. presently there are only five studies that have compared the two modalities of treatment. but, due to the lack standardization of variables, procedure, follow-up imaging and reporting of outcomes in the past studies, it is imperative to conduct study that is prospective and randomized in nature. the present study is randomized in nature, comparing the stone free rate and complications rate between sr-urs and f-urs for the treatment of pus, whereby the preoperative assessments, procedure and reporting of outcomes will all be standardized.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * single proximal ureteric stone indicated for active treatment with ureteroscopy (stented or non-stented) exclusion criteria: * solitary kidney * bilateral ureteric stones * ipsilateral multiple simultaneous ureteric stones * ipsilateral kidney stone * active uti * coagulopathy diseases * ipsilateral ureteral anomalies, ureteral disorder (tumor or stricture) or previous ureteral open surgery. * pregnant patients. * unable to give informed consent. * patient is not agreeing to go through the randomization.

Keywords: urolithiasis ureteroscopy ureteric stone flexible ureteroscopy semi-rigid ureteroscopy
factors associated with sub - targeted therapeutic dose of renin - angiotensin blockage among chronic heart failure with reduced ejection fraction patients

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: objective: to analyze factors associated with thai heart failure with reduced ejection fraction patients who received sub-target doses of angiotensin converting enzyme inhibitors (aceis), angiotensin receptor-neprilysin inhibitors (arnis), and angiotensin receptor blockers (arbs). methods: the retrospective cohort study was designed to collect data on thai heart failure with reduced ejection fraction patients at out-patient clinic, trat hospital and phrapokklao hospital from january 2016 to december 2020. thirteen factors were analyzed to determine their association with the sub-target group.


Eligibility criteria:
inclusion criteria: * patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%. * received one of aceis,arbs,arni drugs. exclusion criteria: * electronic medical records was not complete enough to analyse. * patients who had history of heart transplantation or had heart transplantation plan in last 12 months.
phase iii study of gemcitabine compared with uft in patients with completely resected pathological stage ib-iiia non small cell lung cancer

Conditions: Lung Cancer

Summary: to estimate the efficacy of gemcitabine monotherapy compared to uft as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. completely resected non small cell lung cancer 2. no prior anti cancer treatment for thoracic malignancy exept for this operation 3. pathological stage ib, ii, and stage iiia with only one station of n2 disease 4. ps 0-1 5. age 20-75 6. adequate organ function for chemotherapy 7. written informed consent exclusion criteria: 1. small cell lung cancer or low grade malignancy of lung cancer 2. incomplete resection 3. apparent interstitial pneumonitis at chest rentogenogram 4. inadequate condition for chemotherapy
a study of stem cells and filgrastim

Conditions: HIV Infections

Summary: to determine the safety of stem cell harvesting after administration of filgrastim ( g-csf ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of hiv-1 infection as well as in hiv-negative volunteers. to determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure.

patients and volunteers receive seven daily subcutaneous injections of g-csf. on days 5 and 6 of drug administration, patients have peripheral blood mononuclear cells harvested by leukapheresis. hiv-positive patients are stratified into three cohorts based on cd4 count and presence of symptoms. if no increase in number of harvested stem cells and no grade 4 bone pain toxicity occur in two of the first three patients in a cohort, then the last three patients in that cohort will receive a dose escalation. patients are followed for 24 weeks.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * pcp prophylaxis. * antiretroviral therapy in patients with cd4 counts \<= 500 cells/mm3. * narcotic analgesics for grade 3/4 bone pain toxicity. patients must have: * hiv infection. * hiv infected patients with cd4 count \> 500 cells/mm3 must be asymptomatic. patients with cd4 count 200-500 cells/mm3 may be either asymptomatic or symptomatic but must not have aids. patients with cd4 count \< 200 cells/mm3 may or may not have aids-defining conditions. * no antiretroviral therapy within the past 30 days in patients with asymptomatic disease and cd4 count \> 500 cells/mm3. * stable antiretroviral therapy for the past 60 days if cd4 count \<= 500 cells/mm3. * suitable venous access. prior medication: allowed: * prior antiretroviral therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * current malignancy. * any medication condition that interferes with study evaluation. * known hypersensitivity to e. coli-derived proteins (e.g., insulin, human growth hormones). concurrent medication: excluded: * acute treatment for serious opportunistic infection. * systemic cytotoxic chemotherapy. concurrent treatment: excluded: * systemic radiation therapy. patients with the following prior conditions are excluded: * prior malignancy. * leukapheresis or lymphopheresis within the past 180 days. * significant active cns disease or seizures within the past year. prior medication: excluded: * g-csf or gm-csf within the past 6 months. * investigational antiretrovirals within the past 30 days. * treatment for opportunistic infection within the past 14 days. active alcohol or substance abuse.

Keywords: granulocyte colony-stimulating factor acquired immunodeficiency syndrome aids-related complex stem cells
adolescent knee pain (ak-pain) prognostic tool

Conditions: Knee Pain

Summary: the overall aim of this study is to develop and test a prognostic tool for knee pain in children and adolescents to be used in general practice. by using the tool, general practitioners will be able to allocate the patient to a category of risk (e.g. low/medium/high) of recurrent or persistent knee pain at 3 months and 6 months, and to subsequently provide a treatment that is specific to the category of risk of the patient.

one in three children and adolescents experience knee pain, and one in two will have a poor long-term prognosis with low quality of life and impaired physical activity levels. every year 119 - 200 children and adolescents per 10,000 registered patients consult their general practitioner for knee pain, and a variety of treatments are delivered, despite similar symptoms and patients' characteristics. however, the proportion of children and adolescents with a poor prognosis is high, which suggests that there is an urgent need to support the general practitioners in identifying those at high risk of a poor outcome early on, in order to better allocate resources. this project will develop a user-friendly prognostic tool to support general practitioners' management of children and adolescents' knee pain. clinically relevant prognostic factors for child and adolescent knee pain were identified using systematic reviews and meta-analysis of individual participant data. following feedback from general practitioners and children and adolescents on the content and understanding, the tool was piloted and implemented in general practice. a cohort of approximately 300 children and adolescents will be recruited from general practices and followed-up for up to 6 months (the baseline starting date is july 2019 and the follow-up will end in july 2020) clinically meaningful risk groups (e.g. low/medium/high) for the recurrence and persistence of knee pain (at 3- and 6-months) will be identified. this tool will allow general practitioners to provide children and adolescents an optimal stratified care, by matching treatments to patients' prognostic profile.

Eligibility criteria:
inclusion criteria: * children and adolescents (aged 8-19 years old) who consult their general practitioner because of their knee pain (of both traumatic and non-traumatic origin) during a period of recruitment of 6 months (starting in july 2019) exclusion criteria: * age below 8 years old or over 19 years old * consultation for musculoskeletal pain only in a body region different from the knee * pain originated by different conditions (e.g. cancer, infections) * child is vulnerable (e.g. he/she has experienced a recent trauma and the distress may have an impact on the self-report making it not valid) * inability to take part to the study because of inability to understand or comply
melody registry follow-up study

Conditions: Congenital Heart Disease (CHD)

Summary: extension of the melody registry, to assess longterm follow-up clinical results of melody valve implantation after its commercialization in europe / ous


Eligibility criteria:
inclusion criteria: * previous inclusion in the melody registry exclusion criteria: * none
feasibility study for identifying anti capsular antibody protection against invasive group b streptococcus (gbs) disease in newborns of 0-6 days age (early onset disease [eod]) as well as among infants of 7-90 days age (late onset disease [lod])

Conditions: Streptococcus Agalactiae

Summary: the purpose of this study is to evaluate antibody levels against group b streptococcus in mothers and the risk of developing invasive group b streptococcus disease in newborns of less than 6 days age as well as infants of age less than 90 days age.


Eligibility criteria:
inclusion criteria: * pregnant women (irrespective of gestational age staging or underlying comorbidities) attending for antenatal care at chris hani baragwanath academic hospital (chbah) or an allied antenatal clinic and/or delivering at the participating delivery center (chbah) * subjects aged ≥18 years. * able to understand and comply with planned study procedures. * provides written informed consent. exclusion criteria: • subjects refusing to consent to study participation.

Keywords: streptococcal disease feasibility infants
a study of long-term treatment with deferasirox in patients with beta-thalassemia and transfusional hemosiderosis

Conditions: Beta-Thalassemia; Hemosiderosis

Summary: because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. this study will evaluate the efficacy, safety and tolerability of deferasirox.


Eligibility criteria:
inclusion criteria: * beta-thalassemia outpatients with transfusional hemosiderosis and unable to be chelated with deferoxamine (dfo) due to dfo being contra-indicated and/or due to documented unacceptable toxicity of dfo or documented poor response to dfo despite proper compliance, or documented non-compliance to dfo, with serum ferritin ≥ 500 ng/ml and lic ≥ 2 mg/fe/g dw liver * beta-thalassemia outpatients with transfusional hemosiderosis treated with deferiprone exclusion criteria: * means levels of alt \> 300 u/l * serum creatinine above upper limit of normal * active hepatitis c or chronic hepatitis b receiving specific treatment

Keywords: thalassemia (beta-thal. major) transfusional hemosiderosis deferasirox beta-thalassemia major patients unable to be chelated with deferoxamine or deferiprone
inhaled iloprost in the treatment of patients with pulmonary hypertension up to 4 years

Conditions: Pulmonary Hypertension

Summary: this is an open-label, uncontrolled, prospective long-term observation of specific drug in the treatment of patients with pulmonary hypertension up to 4 years. 160 patients with primary (idiopathic and familial) pulmonary hypertension (ph) or pulmonary arterial hypertension (pah) due to scleroderma with new york heart association (nyha) functional class and exercise capacity, defined as class iii and iv planned to enroll. efficacy, safety and tolerability of the drug and the survival of the patients will be observed.


Eligibility criteria:
inclusion criteria: * patients who has pulmonary hypertension treated with inhaled iloprost older than 18 years old. * primary (idiopathic and familial) pulmonary hypertension (ph) with new york heart association (nyha) functional class and exercise capacity, defined as class iii and iv. * pulmonary arterial hypertension (pah) due to scleroderma with new york heart association (nyha) functional class and exercise capacity, defined as class iii and iv. * patients who signed written informed consent. exclusion criteria: * severe coronary heart disease or unstable angina; myocardial infarction within the last six months; decompensated cardiac failure if not under close medical supervision; * severe arrhythmias; * cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months. * pulmonary hypertension due to venous occlusive disease. * congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension. * pregnancy and lactation * age below 18

Keywords: pulmonary hypertension inhaled iloprost efficacy safety tolerability survival nyha class iii and iv
immunogenicity and safety study to assess influenza vaccine formulated with haemagglutinin (ha) antigen from two suppliers

Conditions: Influenza

Summary: the purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine inflexal v using two different ha antigen suppliers (adimmune and csl), in groups of young and elderly adults, using the ema (european medicines agency) regulation as a guideline.

the objectives of this study are to evaluate the humoral immunogenicity and safety of the parenteral formulation of the 2010/2011-season influenza vaccine, inflexal v, using ha antigen obtained from 2 different production facilities, and to compare the immunogenicity of both formulations to pre-defined ema criteria for the annual relicensing of seasonal influenza vaccines. the evaluation will be done in young adults and elderly.

Eligibility criteria:
inclusion criteria: * healthy female and male adults * aged ≥18 years on day 1 * written informed consent exclusion criteria: * acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * acute febrile illness (≥38.0 °c) * prior vaccination with an influenza vaccine (including the h1n1 pandemic swine flu vaccine) in the past 330 days * known hypersensitivity to any vaccine component * previous history of a serious adverse reaction to influenza vaccine * history of egg protein allergy or severe atopy * known blood coagulation disorder * chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed) * known immunodeficiency (incl. leukemia, cancer, hiv seropositivity) * investigational medicinal product received in the past 3 months (90 days) * treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days) * pregnancy or lactation * participation in another clinical trial * employee at the investigational site, or spouse and children of the investigator, or relative living in the same household as the investigator and/or are dependent on the investigator * suspected non-compliance

Keywords: influenza virus vaccination immunisation
a new prediction mode for predicting the risk of pressure injury in patients undergoing liver transplantation

Conditions: Liver Transplantation

Summary: pediatric population is at a high-risk of pressure injury (pi). patients undergoing liver transplantation are more prone to pis compared with other types of surgery. however, there is a lack of sensitive and specific assessment tools for the risk of pi in patients undergoing liver transplantation. how to accurately predict the incidence of pi in patients undergoing liver transplantation is needs to be urgently eliminated. the study is conducted in the renji hospital, school of medicine, shanghai jiaotong university which is the largest liver transplantation center in china.

data of 1200 eligible patients undergoing liver transplantation between july 2018 and june 2021 are selected.the sample size was randomly divided into 70% discovery set and 30% validation set according to 7:3. 70% of the discovery dataset are used for the establishment of risk prediction model. the univariate analysis is used to evaluate pi-associated risk factors. in addition, a multivariate logistic regression model is developed using selected variables and p\<0.05 in the univariate analysis is used to identify independent risk factors for pis. the odds ratio for each independent variable is determined with a 95% confidence interval. finally, a nomogram of predictive model is generated on the basis of the results of multivariate analysis.discrimination capability, calibration degree, and clinical value will be used to verify the efficacy of the prediction model. this study develops and validates a prediction model for predicting the risk of pi in patients undergoing liver transplantation. using this prediction model, we will develop decision-support systems to prevent pi in the future.

Eligibility criteria:
inclusion criteria: * undergoing liver transplantation surgery (i.e., living-donor liver transplantation and deceased donor liver transplantation) * patients undergoing the first surgery during their hospitalization exclusion criteria: * a history of pi before undergoing surgery * patients with skin disease that could affect observation of skin and the outcome * patients who died during surgery

Keywords: pressure injury liver transplantation predictive mode
endothelial progenitors in aortic stenosis: association with aortic stenosis progression and severity

Conditions: Aortic Stenosis; Cardiac Death

Summary: there is a correlation between endothelial progenitor cells (stem cells) and stenosis of the aortic valve.

degenerative aortic valve (av) stenosis (as) is the most common valvular disease and increases in prevalence with age. severe aortic valve stenosis accounts for considerable disease and death, especially in older patients. aortic valve stenosis is the primary indication for valve replacement in western countries, and the number will only increase as elderly people are a growing subpopulation. measures to identify av disease earlier, to identify factors that influence disease progression and treat av disease pharmacologically or with less invasive approaches would be a significant improvement over the current standard of care. these advances will only be possible with a better understanding the mechanisms underlying valve development and disease. preliminary data suggest a novel pathophysiological concept for impaired valvular endothelial cells regeneration, leading to the progression of age-associated calcific av disease and a potential treatment target is the disrupted endothelial cell layer of the valve leaflet. the research objectives are: 1. to assess the number and function of endothelial progenitor cellss and apoptotic endothelial progenitor cellss in patients with mild, moderate and severe aortic stenosis. 2. to study the association between aortic stenosis progression, severity, symptoms and left ventricular function and the number and function of circulating endothelia progenitor cells. by understanding the correlation between valve severity, left ventricular longitudinal function and endothelial progenitor cells we will indentify high risk patients population that need early intervention. we hope to add new information on the pathogenesis of aortic stenosis and to indentify factors that predict disease progression.

Eligibility criteria:
inclusion criteria: * patients with aortic stenosis * control with aortic stenosis exclusion criteria: * no

Keywords: aortic stenosis
monitoring of the cerebral tissue oxygenation and perfusion in the adapting climber during sleep in high altitude

Conditions: Environmental Sleep Disorder; Cheyne-Stokes Respiration; Altitude Sickness

Summary: one of the major challenges in adapting to high altitudes is that with increasing altitude sleeping quality declines rapidly. thus, the night sleep can only provide limited to none regeneration. it usually takes a prolonged stay at a constant altitude to adapt sufficiently to the altitude and to have a refreshing night sleep. 1975 reit et. al showed in their eeg-recordings that the sleep architecture (the regular succession of the particular sleep phases) is disturbed by repeating arousals which occur due to an irregularity in the breathing rhythm. the purpose of this study is to create a better understanding of the underlying mechanisms that lead to failed acclimatization and ams, due to sleep disturbance.

under sea level conditions humans breath between 10 and 12 times per minute. the breathing cycle in high altitude is accelerated. if the conscious breathing control vanishes during sleep a periodic breathing with alternating episodes of hyperventilation and apnea is the result. this circumstance causes repetitive arousals that do not allow a normal sleep pattern. the associated adverse effects are fatigue, slow or failed acclimatization, weakening of the immune system, lack of motivation and the disability to make rational decisions. sleep deprivation is a common reason for the abortion of a trip, accidents and severe forms of acute mountain sickness (ams).

Eligibility criteria:
inclusion criteria: * age: 18 - 80 years * voluntary participation in an expedition to mount kilimanjaro exclusion criteria: * obstructive or restrictive respiratory disorder * hemodynamic relevant cardiac defect * sleep disorder

Keywords: high altitude acute mountain sickness sleep disorder periodic breathing hyperventilation apnea